NEW YORK (GenomeWeb) – Agendia said Tuesday that updated guidelines from the European Group on Tumor Markers named the firm's MammaPrint 70-gene signature test "as the first and currently the only multigene test of its kind deemed to have level 1A evidence for its clinical use."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.